TRI-ME Trial: A new treatment trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Researchers at Deakin University are investigating if a potential new treatment is effective in treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Researchers at Deakin University are investigating if a potential new treatment is effective in treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This study will assess the effectiveness of the medication in a high-quality, clinical trial.
In a recent drug screening program, the medication showed promising potential to address the key elements of ME/CFS by reversing mitochondrial dysfunction – the likely pathway in ME/CFS.
The medication works to improve the efficiency of how the body creates energy by promoting specific energy production pathway.
Key Points for Participation
• There is no cost involved for participants in the trial
• Participants can continue on their usual treatments
• The trial will be held over 8 weeks and involve a total of 5 sessions
• Participants will be randomly allocated to receive either the active medication or placebo
If you would like to receive more information or enquire about participating, please contact us via email or the website.
Ethics approval number: Barwon Health HREC 23/196
